Back to 
Cullen/Frost Bankers, Inc.
Cullen/Frost Bankers, Inc.
XLO
Showing 0 of 3 quarters
Position history for Cullen/Frost Bankers, Inc.'s holdings in Xilio Therapeutics, Inc.
No. Cullen/Frost Bankers exited its XLO (Xilio Therapeutics) position in Q1 2024. Its Q4 2023 13F listed 100 shares worth $55. Cullen/Frost Bankers first reported XLO in Q3 2023 and held it in 2 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.